Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977151 | 1.00 | BACE1 (0.61) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL10372644 | 1.00 | BACE1 (0.61) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL9464209 | 0.88 | BACE1 (0.62) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL9464207 | 0.88 | BACE1 (0.62) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL69553 | 0.87 | BACE1 (0.60) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL69552 | 0.87 | BACE1 (0.60) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL23618911 | 0.86 | BACE1 (0.61) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL1133142 | 0.86 | BACE1 (0.61) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL10489559 | 0.86 | BACE1 (0.61) | BACE1HTTSMN1; SMN2CA1CA2 | |
| SCHEMBL23618750 | 0.85 | NPC1 (0.63) | BACE1SMN1; SMN2NFKB1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008083975-A1 | LIGHT-STABILIZED COMPOSITION | ISDIN S.A. (ES) | 2008-07-17 | — | — | WO | claimed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4373886-A1 | AN ADDITIVE MIXTURE FOR STABILIZATION OF ORGANIC MATERIAL | BASF SE (DE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024037851-A1 | USE OF ADDITIVES FOR IMPROVING THE PROCESSING OF POLYETHYLENES | BASF SE (DE) | 2024-02-22 | — | — | WO | disclosed |
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| WO-1999067223-A2 | TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS CONTAINING HINDERED PHENOLS | CYTEC TECH CORP (US) | 1999-12-29 | — | — | WO | disclosed |
| CN-1218471-A | Carboline derivatives | ICOS CORP (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0487485-A2 | Weather-resistant powder coating compositions | U C B, S.A. (BE) | 1992-05-27 | — | — | EP | disclosed |
| EP-0201823-B1 | NOVEL INTERMEDIATES FOR THE PRODUCTION OF PHARMACEUTICALS | LILLY INDUSTRIES LIMITED (GB) | 1990-12-05 | — | — | EP | disclosed |
| US-4963578-A | LEUKOTRIN ANTAGONISTS; ANTIALLERGENS | LILLY INDUSTRIES LIMITED (GB) | 1990-10-16 | — | — | US | disclosed |
| US-RE33300-E | LEUKOTRIENE ANTAGONISTS; ANTIALLERGENS | ELI LILLY AND COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0134111-B1 | ARALIPHATIC SULPHIDES,SULPHONES AND SULPHOXIDES AND THEIR PHARMACEUTICAL USE | Lilly Industries Limited (GB) | 1988-12-07 | — | — | EP | disclosed |
| US-4665189-A | LEUKOTRIENE ANTAGONISTS | LILLY INDUSTRIES LIMITED (GB) | 1987-05-12 | — | — | US | disclosed |
| EP-0201823-A2 | Novel intermediates for the production of pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1986-11-20 | — | — | EP | disclosed |
| EP-0134111-A1 | Araliphatic sulphides,sulphones and sulphoxides and their pharmaceutical use | Lilly Industries Limited (GB) | 1985-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | BACE1 122/4885HTT 2458/4885SMN1; SMN2 4857/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | BACE1 27/4885HTT 2327/4885SMN1; SMN2 2006/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | BACE1 122/4885HTT 2458/4885SMN1; SMN2 4857/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | BACE1 80/4885HTT 1122/4885SMN1; SMN2 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.